ClinicalTrials.gg
Status unknownNCT00053105Updated Jul 7, 2009

Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma

A Phase 1 interventional study of cisplatin and cytarabine in Lymphoma, sponsored by Theradex. Status unknown at 7 sites in United States. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2009-07-07.

Sponsored by Theradex · Phase 1, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Mar 2003), so the status shown — last known as Active, not recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 24 studies testing cisplatin in Lymphoma — 1 open to participants now, 1 under way, none of them phase 3. Cisplatin · Lymphoma.

Started
2002
the only one that year
Phase 1
2 of 24
none open now
Registered
13th of 24
by date
Lead sponsor
2 of 24
Theradex

Among the 24 studies testing cisplatin in Lymphoma, this one is the only one that started in 2002, is one of 2 in phase 1, and was the 13th registered.

Lymphoma

3,018 studies on the registry are indexed under Lymphoma; 433 are open to participants now.

Browse Lymphoma studies →

Open to participants now

1 of the 24 studies testing cisplatin in Lymphoma is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About cisplatin

Cisplatin: first FDA approval 1978 (PLATINOL-AQ). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 346 Lymphoma studies recruiting now, 227 (66%) set no upper age limit and 78 (23%) stop at 75 or younger; 77 take children under 18; 20 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies testing cisplatin in Lymphoma, or all of them as a file.
02

Study summary

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.

PURPOSE: Phase I trial to study the effect of combination chemotherapy on the body when treating patients who have relapsed or refractory aggressive non-Hodgkin's lymphoma.

Read the detailed description

OBJECTIVES:

  • Determine the maximum tolerated dose and recommended dose of pixantrone when administered with cytarabine, methylprednisolone, and cisplatin in patients with relapsed or refractory aggressive non-Hodgkin's lymphoma.
  • Determine the dose-limiting toxic effects of this regimen in these patients.
  • Determine the relationship between toxicity and systemic exposure to this regimen in these patients.
  • Determine the safety of this regimen in these patients.
  • Assess the pharmacokinetics of this regimen in these patients.
  • Determine, preliminarily, the efficacy of this regimen in these patients.

OUTLINE: This is an open-label, non-randomized, multicenter, dose-escalation study of pixantrone.

Patients receive pixantrone IV over 1 hour on day 1, methylprednisolone IV over 15 minutes on days 1-5, cisplatin IV over 30 minutes on days 1-4, and cytarabine IV over 2 hours on day 5. Treatment repeats every 21 days for at least 8 courses in the absence of disease progression or unacceptable toxicity.

Cohorts of 3-6 patients receive escalating doses of pixantrone until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which no more than 2 of 6 patients experience dose-limiting toxicity. Additional patients are treated at the recommended dose, which is defined as the dose preceding the MTD.

Patients are followed every 3 months.

PROJECTED ACCRUAL: Approximately 3-30 patients will be accrued for this study.

03

Conditions studied

  • Lymphoma

Keywords

  • recurrent adult diffuse large cell lymphoma
  • recurrent grade 3 follicular lymphoma
  • recurrent cutaneous T-cell non-Hodgkin lymphoma
  • recurrent adult immunoblastic large cell lymphoma
04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

DISEASE CHARACTERISTICS:

  • confirmed aggressive non-Hodgkin's lymphoma (NHL) including the following:

    • Diffuse large B-cell lymphoma
    • Transformed NHL
    • Follicular large cell lymphoma
    • Peripheral T-cell lymphoma
    • Unclassified aggressive histology (immunoblastic lymphoma)
  • Must have received 1 to 3 prior chemotherapy treatment regimens (may include doxorubicin up to a cumulative dose of no greater than 450 mg/m\^2)
  • No Burkitt's lymphoma, lymphoblastic lymphoma, or mantle cell lymphoma

PATIENT CHARACTERISTICS:

Age

  • 18 to 64

Performance status

  • WHO 0-1

  • At least 3 months

Hematopoietic

  • at least 1,500/mm\^3*
  • count at least 100,000/mm\^3* NOTE: *Lower values may be accepted if evidence of bone marrow involvement

Hepatic

  • no greater than 1.5 times (ULN)**
  • Alkaline phosphatase no greater than 2 times ULN**
  • or ALT no greater than 2 times ULN**
  • No history or clinical symptoms of or C virus NOTE: **Higher values may be accepted if evidence of liver involvement

Renal

  • Creatinine no greater than 1.5 mg/dL

Cardiovascular

  • at least 50% by MUGA
  • No cardiovascular abnormalities
  • No class II-IV heart disease
  • No myocardial infarction within the past 6 months
  • No severe arrhythmia
  • No uncontrolled hypertension

Other

  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective during and for at least 6 months after study
  • No history or clinical symptoms of
  • No clinically significant neurological abnormalities
  • No serious uncontrolled infection (NCI CTC grade 3-4)
  • No condition that would place the patient at undue risk or interfere with the study results

PRIOR CONCURRENT THERAPY:

Biologic therapy

  • At least 3 months since prior radioimmunotherapy

Chemotherapy

  • See Disease Characteristics
  • At least 4 weeks since prior chemotherapy
  • At least 1 year since prior platinum or cytarabine (unless complete response to treatment)
  • At least 2 years since prior fludarabine or nitrosoureas
  • No prior cumulative cisplatin greater than 600 mg/m\^2

Endocrine therapy

  • Not specified

Radiotherapy

  • See Biologic therapy
  • At least 4 weeks since prior radiotherapy
  • No prior radiotherapy to the whole pelvis

Surgery

  • At least 1 week since prior minor surgery and recovered
  • At least 4 weeks since prior major thoracic and/or abdominal surgery and recovered

Other

  • At least 1 month since prior drugs
  • Recovered from prior therapy
  • No other concurrent investigational drugs
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment

Interventions

06

Study locations

7 sites
  • Arizona Clinical Research Center
    Tucson, Arizona 85712, United States
  • Highlands Oncology Group
    Springdale, Arkansas 72764, United States
  • USC/Norris Comprehensive Cancer Center and Hospital
    Los Angeles, California 90033-0800, United States
  • Marlene and Stewart Greenebaum Cancer Center, University of Maryland
    Baltimore, Maryland 21201, United States
  • Ireland Cancer Center
    Cleveland, Ohio 44106-5055, United States
  • Boston Baskin Cancer Group, University Tennessee
    Memphis, Tennessee 38104, United States
  • University of Texas - MD Anderson Cancer Center
    Houston, Texas 77030, United States
07

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 7, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT00053105
Lead sponsor
Theradex
First posted
Jan 28, 2003
Start date
Feb 2002
Last update
Jul 7, 2009

Study contacts

Luis Fayad, MD
study chair · M.D. Anderson Cancer Center
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2003. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cisplatin · Cytarabine · Methylprednisolone

Start the discussion